Dutch Life Insurance Market and Ageas Reinstatement

Goldman Sachs reiterates 'Buy' on Dutch insurers NN and ASR, citing defensive balance sheets and AI tailwinds, while reinstating Ageas at 'Neutral' due to group complexity.

Key Takeaways

• 1.Benelux insurers (Ageas, ASR, and NN) have significantly outperformed broader indices like the STOXX600 (+11ppts) and SXIP (+19ppts) over the last year.
• 2.Dutch Life insurers (NN and ASR) remain attractive 'Buy' ratings due to defensive balance sheets, lack of USD currency exposure, and potential AI-driven operating cost benefits.
• 3.Ageas is reinstated at a Neutral rating as it enters an execution phase following significant M&A (esure, AG Insurance), with analysts citing group complexity as a limiting factor.

Table of Contents

• Benelux insurers have outperformed
• Dutch Life: Value in top-down positioning; reiterate Buy recommendations
• Reinstate rating on Ageas at Neutral
• Benelux insurance has outperformed
• Capital return and OCG yields underpin the subsector
• Business mixes have evolved
• Uniquely positioned subsector against current macro, pricing and technological disruption backdrop
• Subsector positioning: Further to run for the Dutch Life companies
• Ageas Investment Summary: Reinstate at Neutral, PT €70
• Ageas shares have outperformed
• Moving to an execution phase
• We see limited upside to esure cost synergies
• We are not expecting further Belgium M&A in the near term
• 2026 guidance is relatively conservative
• We believe Ageas shares are fairly valued
• GSe valuation based on Price to Adjusted Tangible Book Value
• Risks to our view
• Summary financials

Document Preview

Page 1 of 5

Subscribe for full accessStart Free Trial